表紙
市場調查報告書

RNA技術促進醫藥品探索·開發 (Drug Discovery and Development)

RNA Technologies Enabling Drug Discovery and Development

出版商 Frost & Sullivan 商品編碼 763648
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
RNA技術促進醫藥品探索·開發 (Drug Discovery and Development) RNA Technologies Enabling Drug Discovery and Development
出版日期: 2018年12月28日內容資訊: 英文 50 Pages
簡介

本報告提供RNA治療藥產業相關之產業推動因素與課題,技術概要與趨勢,臨床實驗平台分析,IP形勢概要,創新者的簡介,及未來發展藍圖等觀點下的總括性分析資訊。

第1章 摘要整理

第2章 RNA治療藥:產業概要

  • RNA是變革治療平台的新星
  • 產業的推動因素與課題
  • RNA輸送(給藥):技術區分
  • RNA治療藥:技術區分
  • RNA治療藥整體分子的考察

第3章 技術趨勢·臨床實驗平台

  • SSO治療引起的選擇性splicing
  • SMA和DMD SSO療法的臨床管道分析
  • ASO的轉錄後修飾
  • ASO療法的臨床管道概述
  • ASO治療的新興臨床管道
  • 早期ASO療法
  • 核酸適體的配體結合之阻礙
  • 核酸適體治療藥物臨床實驗平台分析
  • RNA干擾療法平台的標誌性年份
  • RNA干擾療法臨床分析
  • mRNA治療藥的新興形勢概要
  • mRNA治療藥的臨床實驗平台分析
  • saRNA:RNA型治療藥的參與企業越來越多

第4章 專利形勢概要

  • ASO技術的專利趨勢
  • RNAi平台的專利趨勢
  • mRNA技術的專利趨勢

第5章 革新的簡介

  • 用於增強疾病管理的標的型RNAi技術
  • 實現RNAi治療的標的型輸送(給藥)
  • 開發穩定和非免疫原性mRNA療法
  • 加強新型RNA治療和輸送(給藥)平台
  • 實現強效反義治療

第6章 未來展望

  • RNA平台可能改變衛生保健的未來
  • RNA技術的未來情勢

第7章 成長機會·推薦行動

  • 成長機會1:ASO治療藥
  • 成長機會2:RNAi治療藥
  • 成長機會3:mRNA治療藥
  • 成功·成長的策略要求

第8章 主要產業的影響者

目錄
Product Code: D86A

Redefining the Future of Healthcare through Groundbreaking RNA Therapies

This research service encompasses a comprehensive analysis of RNA therapy industry from the following perspectives:

  • Industry Drivers and Challenges
  • Technology Snapshot and Trends
  • Clinical Pipeline Analysis
  • Overview of the IP Landscape
  • Innovator Profiles
  • Future Roadmap

The RNA therapy platforms covered include:

  • Splice-Switching Oligonucletides (SSO)
  • Other Anti-Sense Oligonucleotide (ASO)
  • Aptamers
  • RNA-interference
  • mRNA
  • saRNA

An appendix is included, comprising lists of major industry influencers found in the study.

Table of Contents

1.0. EXECUTIVE SUMMARY

  • 1.1. Research Scope: RNA Therapies Redefining the Healthcare Landscape
  • 1.2. Analysis Framework: Frost & Sullivan's Core Value
  • 1.3. Research Methodology: Five Steps Towards Success
  • 1.4. Key Findings

2.0. RNA THERAPIES: INDUSTRY OVERVIEW

  • 2.1. RNA is the Rising Star of Transformative Therapy Platforms
  • 2.2. Industry Accelerators and Challenges
  • 2.3. RNA Delivery: Technology Segmentation
  • 2.4. RNA Therapies: Technology Segmentation
  • 2.5. Molecular Insights Across RNA Therapy

3.0. TECHNOLOGY TRENDS & CLINICAL PIPELINE

  • 3.1. Alternative Splicing Induced by SSO Therapies
  • 3.2. Clinical Pipeline Analysis for SSO Therapies for SMA and DMD
  • 3.3. Post-transcriptional Modifications by ASO
  • 3.4. Clinical Pipeline Overview for ASO Therapies
  • 3.5. Emerging Clinical Pipeline for ASO Therapies
  • 3.6. Early Phase ASO Therapies
  • 3.7. Inhibition of Ligand Binding by Aptamer
  • 3.8. Clinical Pipeline Analysis for Aptamer Therapies
  • 3.9. Landmark Year for RNA Interference Therapy Platform
  • 3.10. Clinical Analysis of RNA Interference Therapeutics
  • 3.11. Overview of the Emerging Landscape for mRNA Therapies
  • 3.12. Clinical Pipeline Analysis of mRNA Therapies
  • 3.13. saRNA: The Rising Participant in RNA-based Therapies

4.0. OVERVIEW OF THE PATENT LANDSCAPE

  • 4.1. Patenting Trends for ASO Technologies
  • 4.2. Patenting Trends for RNAi Platforms
  • 4.3. Patenting Trends for mRNA Technologies

5.0. INNOVATION PROFILES

  • 5.1. Targeted RNAi Technology for Enhanced Disease Management
  • 5.2. Enabling Targeted Delivery of RNAi Therapeutics
  • 5.3. Developing Stable and Non-immunogenic mRNA Therapies
  • 5.4. Fueling Novel RNA Therapy and Delivery Platforms
  • 5.5. Enabling Potent Antisense Therapeutics

6.0. FUTURE PERSPECTIVES

  • 6.1. RNA Platforms likely to Transform the Future of Health & Wellness
  • 6.2. Navigating Through The Future Landscape for RNA Technologies

7.0. GROWTH OPPORTUNITIES AND COMPANIES TO ACTION

  • 7.1. Growth Opportunity 1: ASO Therapies
  • 7.2. Growth Opportunity 2: RNAi Therapies
  • 7.3. Growth Opportunity 3: mRNA Therapies
  • 7.4. Strategic Imperatives for Success and Growth

8.0. KEY INDUSTRY INFLUENCERS

  • 8.1. Industry Interactions
  • 8.1. Industry Interactions (continued)
Back to Top